Nuccia Morici

TL;DR: Discontinuation of thienopyridine therapy was the major determinant of ST within the first 6 months, but insufficient information is available to determine whether there is benefit in continuing a thienobyridine beyond 6 months.

TL;DR: The present study does not allow a definite conclusion about the benefit of an EA approach when applied systematically among elderly patients with NSTEACS, and the finding of a significant interaction for the treatment effect according to troponin status at baseline should be confirmed in a larger size trial.

TL;DR: In this large observational study of patients with SCAD, angiographic features significantly influenced the treatment strategy, providing an excellent short- and long-term prognosis.

TL;DR: The present study in elderly patients with acute coronary syndromes showed no difference in the primary end point between reduced-dose prasugrel and standard-dose clopidogrel, suggesting the possibility of reducing ischemic events without increasing bleeding.